

REMARKS

Currently Claims 1-33 are pending, claims 34 and 35 having been canceled. Claims 1, 4-6, 8-11, 13, 14, 16-20, 22, 23, 25, and 27-32 have been amended to place them in form appropriate to US practice, to reduce the filing fee by removing multiple dependencies, and/or to correct typographical errors, and have not been made for reasons substantially related to patentability.

The specification has been amended to include a reference to related applications/claim of priority to the corresponding PCT application and foreign filed application.

Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

Applicants respectfully submit that the present application is in condition for examination and respectfully request the early consideration thereof and the issuance of a Notice of Allowance forthwith.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted:

J. Michael Strickland
Attorney for Applicants
Reg. No. 47,115

Date: _____
GlaxoSmithKline Inc.
Corporate Intellectual Property
Five Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709
Tel. (919) 483-9024
Fax: (919) 483-7988

ABSTRACT

A container having a first part, a second part and a hinge through which the first and second parts are hingeably connected so that the parts are hingeable relative to one another between a first position which places the container in a closed state and a second position which places the container in an open state is disclosed. The first and second parts are also pivotally connected so that the parts are able to be pivoted relative to one another to different angular positions.